More recently, chemoimmunotherapy with the anti-CTLA4 antibody ipilimumab + the anti-PD-1 nivolumab and two cycles of chemotherapy has been approved for clinical use, based on the results of the CheckMate-9LA trials (n = 224 squamous-cell carcinoma patients) [22]. This evidence concerns the gene CTLA4 and squamous cell carcinoma.